Among US postmenopausal women, the use of oral estrogen generally and vaginally administered estrogen products declined in age groups <65 years between 2006 and 2015, a recent study found. Researchers used prescription claims for US commercial health insurance to calculate, in women aged ≥50 years (n=12,007,364), the age-standardized and age-specific annual prevalence of estrogen use by formulation and route of administration during the specified study period. They found:
- The age-standardized annual prevalence of a prescription claim for oral estrogens declined over time, from 83 per 1,000 women in 2007 to 42 per 1,000 women in 2015.
- The age-standardized annual prevalence of a prescription claim for vaginal estrogens peaked in 2011, at 42 per 1,000 women, before declining to 35 per 1,000 women in 2015.
- The age-standardized annual prevalence of a prescription claim for transdermal estrogen fluctuated between 15 and 17 per 1,000 women.
- Annual prevalence rates for vaginal rings and inserts declined over the latter half of the study period in age groups <65 years.
Weissfeld JL, Liu W, Woods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance. [Published online ahead of print December 28, 2017]. Menopause. doi:10.1097/GME.0000000000001054.
This Week's Must Reads
Must Reads in Menopause
Menopause Symptom Burden and Chronic Pain, Menopause; ePub 2019 Mar 4; Gibson, et al
Trends in Menopausal Hormone Therapy, Menopause; ePub 2018 Dec 21; Crawford, et al
Chronic Disease Risk with Vaginal Estrogen Use, Menopause; ePub 2018 Dec 17; Bhupathiraju, et al
Sleep Disturbance After Surgical Menopause, Menopause; ePub 2018 Nov 12; Cho, Kim, et al
Cardiac Autonomic Function in Midlife Women, Menopause; ePub 2018 Jun 18; Fu, et al